ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Synergistic amelioration of glaucoma by exogenous BDNF supplementation and microRNA-93 inhibitors via regulating Rho/ROCK and BDNF/TrkB/CREB signaling pathways.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Interpreting the Black Box: Interpretable Machine Learning and Systems Pharmacology in Small-Molecule Therapeutics.Pharmaceutics · 2026Review
- Benzyl isothiocyanate alleviates neural damage in experimental autoimmune uveitis by modulating the TREM-1/PI3K/AKT signaling pathway.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current study aims to investigate the ameliorative effects of exogenous brain-derived neurotrophic factor (BDNF) supplementation, in combination with microRNA-93 (miR-93) inhibitors, on acute glaucoma mouse models, and to delve into the underlying mechanisms. Oxygen-glucose deprivation/reperfusion (OGD/R)-induced retinal ganglion cells (RGCs) apoptosis was assessed using the MTT assay and flow cytometry. Acute glaucoma was induced by elevating intraocular pressure (IOP) in mice, which were divided into groups receiving PBS, miR-93 inhibitors, BDNF, or combination therapy, alongside a healthy control group. Retinal tissues were analyzed for thickness, ganglion cell layer (GCL) cell counts, and pathological changes. Real-time quantitative PCR (qPCR) and Western blotting assessed mRNA and protein expression related to the Rho/ROCK and BDNF/TrkB/CREB signaling pathways. Rescue experiments employing specific inhibitors and agonists targeting these pathways were conducted to further elucidate the mechanisms involved. The combination therapy demonstrated a significant improvement in the survival of RGCs by inhibiting apoptosis induced by OGD/R. Additionally, this combined treatment ameliorated the elevation of IOP, retinal damage, and reduction in retinal thickness observed in glaucoma models. Notably, the combination therapy resulted in increased ganglion cell layer (GCL) cell counts compared to monotherapy groups, indicating a synergistic effect on retinal preservation (all P < 0.05). Western blot revealed that combination therapy inhibited the Rho/ROCK pathway and ECM-related protein expression, while enhancing BDNF/TrkB/CREB signaling and MMP-related protein expression (all P < 0.05). Rescue experiments showed that BDNF inhibitors and Rho agonists reversed these effects. In conclusion, the combination of BDNF supplementation and miR-93 inhibitors exerts synergistic effects in acute glaucoma by inhibiting the Rho/ROCK pathway and activating the BDNF/TrkB/CREB signaling pathway.
Indexed as
Identifiers
40569368What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.